brand logo

This is a corrected version of the article that appeared in print.

Am Fam Physician. 2020;102(6):335-337

Related letter: Evidence-Based Use of Opioids

This clinical content conforms to AAFP criteria for CME.

Author disclosure: No relevant financial affiliations.

Case Scenario

Mrs. H is a 76-year-old woman with hypertension and type 2 diabetes mellitus complicated by stable chronic kidney disease. Mrs. H also has a degenerative joint disease of the knees and walks with a cane. Her mobility and quality of life are significantly limited by knee pain. Physical therapy, heat, acupuncture, and steroid injections have provided insufficient relief. Nonsteroidal anti-inflammatory drugs (NSAIDs) were discontinued because of kidney disease. Several years ago, Mrs. H's family physician prescribed 5 mg of oxycodone every six hours as needed, and a standing dose of 650 mg of acetaminophen every six hours. This regimen, with range of motion exercises and application of heat, has improved pain and function without adverse effects. Mrs. H takes two to four oxycodone doses per day and has not needed more than the 100 pills prescribed each month. At a recent visit, her physician told her that because of the opioid epidemic and scrutiny by the state medical licensure board, he is no longer comfortable prescribing opioids for her chronic pain. He refers Mrs. H to a pain management specialist. However, when Mrs. H calls several pain specialists' offices, she is told that they no longer accept new patients, only do interventional procedures, or no longer prescribe opioids.

Clinical Commentary

The opioid epidemic in the United States coincided with a steady increase in national opioid prescriptions, peaking in 2012 at more than 255 million, or a rate of 81.3 prescriptions per 100 people.1 Opioid prescribing declined between 2012 and 2017 to 191 million, or 58.7 prescriptions per 100 people.1 In 2017, more than 70,000 people died from a drug overdose (47,600 involving opioids), making it the leading cause of injury-related death in people 25 to 64 years of age.2,3 [corrected] Contributing causes include aggressive pharmaceutical industry marketing, indiscriminate prescribing by clinicians, pressure from regulatory agencies to control pain and improve patient satisfaction, patient misuse and diversion, and increased use of illicit drugs such as heroin and fentanyl.4

Chronic pain is pain that has lasted for longer than three months or the time of normal tissue healing.5,6 Nonpharmacologic treatment options include physical therapy, manipulative medicine, acupuncture, and cognitive behavior therapy. Pharmacologic approaches include opioid and nonopioid analgesics in addition to adjuvant medications such as anticonvulsants, antidepressants, and muscle relaxants.7 The use of nonopioid medications is often restricted by limited effectiveness or adverse effects, such as bleeding, strokes, and cardiovascular and renal disease with NSAIDs.8 Adjuvant medications such as gabapentin (Neurontin) have been used for nonapproved indications (e.g., bone and joint pain) with little evidence of effectiveness.9 These medications are also associated with numerous adverse effects, drug-drug interactions, and the potential for misuse.10

In 2016, the Centers for Disease Control and Prevention (CDC) published guidelines for prescribing opioids for chronic noncancer pain based on an Agency for Healthcare Research and Quality systematic review and expert opinion.11,12 These guidelines were intended for primary care clinicians, who account for approximately one-half of all opioid prescriptions.13 The American Academy of Family Physicians gave the guidelines an Affirmation of Value but did not fully endorse them because of the limited or insufficient evidence to support some recommendations.14

In response to the CDC guidelines, media attention, and increased regulatory scrutiny, many physicians have stopped prescribing opioids for chronic pain. Abrupt opioid discontinuation has left patients with the inability to function, led to opioid withdrawal or pain crises, and caused some to seek relief from illicit opioids.15,16 In 2019, the lead authors of the CDC guidelines clarified that their intention was not to set hard limits on daily opioid doses or cause clinicians to abruptly taper or stop prescribing opioids to patients with chronic pain.17

Already a member/subscriber?  Log In

Subscribe

From $145
  • Immediate, unlimited access to all AFP content
  • More than 130 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available

Article Only

$25.95
  • Immediate, unlimited access to just this article
  • CME credits
  • AAFP app access
  • Print delivery available
Purchase Access:  Learn More

Continue Reading

More in AFP

More in Pubmed

Copyright © 2020 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.